

PREVENTION AND TREATMENT OF PROSTATE CANCER: TECHNOLOGIES AND GLOBAL MARKETS



PHM113A
January 2013

Usha Nagavarapu
Project Analyst

ISBN: 0-89336-381-2

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THIS STUDY	1
INTENDED AUDIENCE	1
SCOPE OF THE STUDY	2
METHODOLOGY	2
INFORMATION SOURCES	2
ABOUT THE AUTHOR	2
RELATED BCC REPORTS	3
BCC ON-LINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
<i>SUMMARY TABLE GLOBAL PROSTATE CANCER MARKET, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL PROSTATE CANCER MARKET, 2010-2017 (\$ MILLIONS)</i>	6
CHAPTER 3 OVERVIEW	8
INTRODUCTION	8
U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS	8
<i>TABLE 1 U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008</i>	9
BIOLOGY OF PROSTATE CANCER	9
PROSTATE GLAND	10
PROSTATE GLAND FUNCTION	11
GROWTH OF THE PROSTATE GLAND	11
TYPES OF PROSTATE CANCER	11
PRECANCEROUS CONDITIONS OF THE PROSTATE	12
Prostatic Intraepithelial Neoplasia (PIN)	12
Proliferative Inflammatory Atrophy (PIA)	12
PROSTATE CANCER DEVELOPMENT AND AGING	12
MECHANISMS OF DISEASE DEVELOPMENT PATHOPHYSIOLOGY	13
FAMILY HISTORY	13
ENVIRONMENTAL FACTORS	14
EPIDEMIOLOGY AND RISK FACTORS	14
HORMONES	14
GROWTH FACTORS	15
<i>TABLE 2 GROWTH FACTORS IMPLICATED IN PROSTATE CANCER</i>	15
GENETICS	16
<i>TABLE 3 PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI</i>	17
MOLECULAR MECHANISMS OF PROSTATE CANCER	17
<i>TABLE 4 IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER</i>	18
THE ANDROGEN RECEPTOR	18
PTEN	18
P53	19
GSTP GENES	19
<i>TABLE 5 MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION</i>	19
PROSTATE-SPECIFIC ANTIGEN	21

TOPIC	PAGE NO.
CAVEOLIN-1	21
EMSY	21
AMACR	21
KLF6	21
NBS1	22
CHEK2	22
MISMATCH REPAIR GENES	22
HOXB13	22
BRCA1 AND BRCA2	22
HEREDITARY PROSTATE CANCER	23
PROSTATE CANCER PREVENTION AND TREATMENT	23
CONCLUSIONS	25
CHAPTER 4 PROSTATE CANCER	27
DETECTION AND DIAGNOSIS	27
DIAGNOSIS	27
How is Prostate Cancer Diagnosed?	27
Tests to Diagnose Prostate Cancer	28
<i>TABLE 6 WHY PSA TESTING?</i>	28
SCREENING, DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCER	28
GUIDELINES FOR PROSTATE CANCER SCREENING	29
RECOMMENDATIONS FOR PROSTATE CANCER EARLY DETECTION	30
<i>TABLE 7 PROSTATE CANCER: MAJOR POINTS</i>	30
NEW PROSTATE CANCER SCREENING GUIDELINES	31
RECENT DEVELOPMENTS	32
Recommendations for Early Cancer Detection	33
<i>TABLE 8 ACS RECOMMENDATIONS FOR THE EARLY DETECTION OF CANCER IN AVERAGE-RISK, ASYMPTOMATIC INDIVIDUALS</i>	33
PROSTATE CANCER SCREENING	34
PSA	34
PSA for Early Detection of Prostate Cancer	34
<i>TABLE 9 PSA TEST: WHY AND WHEN?</i>	35
PSA Testing: Good or Bad?	35
PSA Test's Performance	36
PSA Reference Ranges	37
<i>TABLE 10 AGE-SPECIFIC REFERENCE RANGES FOR SERUM PSA (NG/ML)</i>	37
PSA Testing and Concerns	38
<i>TABLE 11 OTHER CAUSES OF CHANGES IN PSA LEVEL</i>	38
Improvements for the PSA Test	39
<i>TABLE 12 IMPROVEMENTS TO THE PSA TEST</i>	40
PSA Levels and Velocity	40
Post-treatment Management of Prostate Cancer and the PSA Test	41
Pretreatment Staging of Prostate Cancer and PSA Test	41
Potential Benefits of Screening	41
Potential Harm of Screening	42
Economic Consequence of PSA Testing	42
STAGING AND GRADING OF PROSTATE CANCER	42
DIAGNOSTIC BIOPSY	44

TOPIC	PAGE NO.
Prostate Biopsy	44
TEST FOR METASTASIS	45
NEW METHODS IN DEVELOPMENT	46
MicroRNA Patterns	46
Non-mutation Gene Alterations	46
Gene Fusions	46
PCA3	46
Differential Detection of Metabolites	47
Proteo-imaging	47
Protein Patterns in the Blood	47
IMAGING STRATEGIES FOR DIAGNOSIS OF PROSTATE CANCER	47
PROSTATE CANCER PROGNOSIS AND OUTCOMES PREDICTIONS	47
CONCLUSIONS	48
CHAPTER 5 PROSTATE CANCER SCREENING AND DIAGNOSIS	50
DIAGNOSTIC PRODUCTS	50
<i>TABLE 13 PROSTATE CANCER: DIAGNOSIS AND TREATMENT STRATEGY</i>	50
PROSTATE CANCER SCREENING, DIAGNOSIS AND PROGNOSIS	50
<i>TABLE 14 PROSTATE CANCER TESTS</i>	51
PSA TESTS	51
New Types of PSA Tests	52
Percent-free PSA	52
PSA Velocity	52
PSA Density	53
Age-Specific PSA Ranges	53
THE DRE	53
PROSTATE ULTRASOUND AND BIOPSY	53
IMAGING TECHNOLOGIES FOR PROSTATE CANCER	54
Computerized Tomography	54
Magnetic Resonance Imaging	55
Endorectal MRI Technology	56
Magnetic Resonance Spectroscopic Imaging	57
Proton Radiation Therapy	59
High Intensity Focused Ultrasound	60
CONCLUSIONS	61
CHAPTER 6 PROSTATE CANCER: THERAPEUTIC INTERVENTIONS	63
TREATMENT PLAN	63
<i>TABLE 15 TREATMENT OPTIONS FOR PROSTATE CANCER</i>	63
TREATMENT OPTIONS	63
Watchful Waiting or Active Surveillance	64
<i>TABLE 16 FACTORS FOR PROSTATE CANCER TREATMENT PLANNING</i>	64
<i>TABLE 17 GUIDE TO PROSTATE CANCER DIAGNOSIS AND MANAGEMENT</i>	64
SURGERY	64
<i>TABLE 18 TYPES OF SURGERY</i>	65
Radical Prostatectomy	65
SECONDARY THERAPY	66

TOPIC	PAGE NO.
<i>TABLE 19 ADVANTAGES AND DISADVANTAGES OF RADICAL PROSTATECTOMY</i>	66
Counseling about Postoperative Erectile Dysfunction	66
RADIOTHERAPY	67
INTERSTITIAL BRACHYTHERAPY FOR LOW-RISK CANCERS	67
<i>TABLE 20 ADVANTAGES AND DISADVANTAGES OF INTERSTITIAL BRACHYTHERAPY</i>	68
EXTERNAL BEAM RADIOTHERAPY	68
<i>TABLE 21 ADVANTAGES AND DISADVANTAGES OF EXTERNAL BEAM RADIOTHERAPY</i>	69
COMBINED RADIATION THERAPY	69
CRYOTHERAPY	69
<i>TABLE 22 ADVANTAGES AND DISADVANTAGES OF CRYOTHERAPY</i>	70
HIGH-INTENSITY FOCUSED ULTRASOUND	70
<i>TABLE 23 ADVANTAGES AND DISADVANTAGES OF ULTRASOUND</i>	71
FOCAL ABLATION	71
HORMONE THERAPY	71
<i>TABLE 24 HORMONE THERAPY</i>	72
ANDROGEN DEPRIVATION, AN ADJUVANT THERAPY	72
Post-treatment Monitoring	73
CHEMOPREVENTION AND CHEMOTHERAPY	73
IMMUNOTHERAPY	74
NUTRITIONAL THERAPY	75
ERECTILE DYSFUNCTION	75
EMERGING THERAPIES	76
Combination Therapy	76
Therapeutic Vaccines	77
New Drugs for Hormone-Resistance Prostate Cancer	77
Inhibitors of Kinase Signaling Pathways	77
Proteasome Inhibitors	78
Angiogenesis Inhibitors	78
TREATMENT STRATEGIES FOR PROSTATE CANCER BY STAGE	78
<i>TABLE 25 STAGE I PROSTATE CANCER</i>	79
<i>TABLE 26 STAGE II PROSTATE CANCER</i>	79
<i>TABLE 27 STAGE III PROSTATE CANCER</i>	80
<i>TABLE 28 STAGE IV PROSTATE CANCER</i>	80
CHAPTER 7 PROSTATE CANCER THERAPEUTICS IN THE GLOBAL MARKET	82
WHAT IS CANCER?	82
<i>TABLE 29 THERAPEUTICS FOR PROSTATE CANCER TREATMENT</i>	82
DRUGS APPROVED FOR PROSTATE CANCER	82
<i>TABLE 30 APPROVED FDA PROSTATE CANCER DRUGS</i>	83
LUPRON (LEUPROLIDE ACETATE)	83
TAXOTERE (DOCETAXEL)	83
JEVTANA (CABAZITAXEL)	84
ZYTIGA (ABIRATERONE ACETATE)	84
PROVENGE (SIPULEUCEL-T)	84
XGEVA (DENOSUMAB)	84
<i>TABLE 31 COMMON DRUGS FOR TREATMENT OF PROSTATE CANCER</i>	84
AVODART (DUTASTERIDE)	85

TOPIC	PAGE NO.
DRUG DESCRIPTIONS	85
CASODEX (BICALUTAMIDE)	85
<i>FIGURE 1 STRUCTURE OF CASODEX</i>	86
Clinical Pharmacology	86
Clinical Studies	87
ZOLADEX (GOSERELIN ACETATE)	88
<i>FIGURE 2 CHEMICAL STRUCTURE OF ZOLADEX</i>	89
Clinical Pharmacology	89
Clinical Studies	90
Post-Marketing Studies	91
ELIGARD (LEUPROLIDE)	91
<i>FIGURE 3 CHEMICAL STRUCTURE OF ELIGARD</i>	92
Clinical Pharmacology	93
Clinical Studies	93
Post-Marketing Studies	94
NILANDRON (NILUTAMIDE)	94
<i>FIGURE 4 CHEMICAL STRUCTURE OF NILANDRON</i>	95
Clinical Pharmacology	95
Clinical Studies	96
Post-Marketing Studies	96
FLUTAMIDE	96
<i>FIGURE 5 CHEMICAL STRUCTURE OF FLUTAMIDE</i>	97
Clinical Pharmacology	97
Clinical Studies	97
Post Marketing Studies	99
TRIPTORELIN (TRELSTAR)	99
<i>FIGURE 6 CHEMICAL STRUCTURE OF TRELSTAR</i>	99
Clinical Pharmacology	100
Clinical Trials	100
Post-Marketing Studies	101
ESTRAMUSTINE (EMCYT)	102
<i>FIGURE 7 CHEMICAL STRUCTURE OF ESTRAMUSTINE</i>	102
Clinical Pharmacology	103
FIRMAGON (DEGARELIX ACETATE)	103
<i>FIGURE 8 CHEMICAL STRUCTURE OF FIRMAGON</i>	104
Clinical Pharmacology	104
Clinical Studies	105
TAXOTERE (DOCETAXEL)	105
<i>FIGURE 9 CHEMICAL STRUCTURE OF DOCETAXEL</i>	106
Clinical Pharmacology	107
Clinical Studies	108
Post-Marketing Studies	108
JEVTANA (CABAZITAXEL)	108
<i>FIGURE 10 CHEMICAL STRUCTURE OF JEV TANA</i>	109
Clinical Pharmacology	109
Clinical Studies	110
MITOXANTRONE (NOVANTRONE)	111

TOPIC	PAGE NO.
VINORELBINE (NAVELBINE)	111
ZYTIGA (ABIRATERONE ACETATE)	111
<i>FIGURE 11 CHEMICAL STRUCTURE OF ZYTIGA</i>	112
Clinical Pharmacology	112
Clinical Studies	113
PROVENGE (SIPULEUCEL-T)	114
Clinical Pharmacology	115
Clinical Studies	115
OTHER THERAPEUTIC AGENTS	115
<i>TABLE 32 THERAPEUTIC AGENTS FOR PROSTATE CANCER UNDER CLINICAL DEVELOPMENT</i>	116
CHAPTER 8 GLOBAL BURDEN OF CANCER	119
<i>TABLE 33 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 (MILLIONS)</i>	119
<i>FIGURE 12 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 (MILLIONS)</i>	119
GLOBAL PROSTATE CANCER STATISTICS	120
<i>TABLE 34 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (IN THOUSANDS)</i>	121
<i>FIGURE 13 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (IN THOUSANDS)</i>	122
PROSTATE CANCER MORTALITY	123
<i>TABLE 35 GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008</i>	124
<i>FIGURE 14 GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008</i>	125
PROSTATE CANCER BURDEN GLOBALLY	125
<i>TABLE 36 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030</i>	126
<i>FIGURE 15 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030</i>	126
PROSTATE CANCER IN THE U.S.	127
<i>TABLE 37 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011</i>	127
<i>FIGURE 16 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011</i>	127
<i>TABLE 38 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030</i>	128
<i>FIGURE 17 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030</i>	128
<i>TABLE 39 INCIDENCE RATES BY RACE IN THE U.S., 2005-2009 (PER 100,000 MEN)</i>	128
<i>TABLE 40 ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030</i>	129
<i>FIGURE 18 ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030</i>	129
PROSTATE CANCER MORTALITY RATES IN THE U.S.	129
<i>TABLE 41 MORTALITY RATES BY RACE IN THE U.S., 2005-2009 (PER 100,000 MEN)</i>	130
PROSTATE CANCER AND AFRICAN AMERICAN MEN	130
<i>TABLE 42 DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS FOR MALES OF ALL RACES, 2002-2008 (%)</i>	131
<i>TABLE 43 RELATIVE SURVIVAL RATE FOR PROSTATE CANCER PATIENTS</i>	131
SURVIVAL RATES BY STAGE	131
<i>TABLE 44 FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT THE TIME OF DIAGNOSIS (%)</i>	132
PROSTATE CANCER AND CANADA	132
<i>TABLE 45 ESTIMATED PROSTATE CANCER IN CANADA, 2012</i>	132
PROSTATE CANCER AND EUROPE	133
<i>TABLE 46 ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008</i>	133

TOPIC	PAGE NO.
<i>FIGURE 19 ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008</i>	134
PROSTATE CANCER AND UNITED KINGDOM	134
<i>TABLE 47 PROSTATE CANCER DEATHS IN THE U.K., RATE PER 100,000 PEOPLE, 2010</i>	135
<i>FIGURE 20 PROSTATE CANCER DEATHS IN THE U.K.: RATE PER 100,000 PEOPLE, 2010</i>	135
PROSTATE CANCER IN ASIA	135
OTHER NATIONS	136
JAMAICA	136
AUSTRALIA	136
CONCLUSIONS	136
CHAPTER 9 PROSTATE CANCER AND DIAGNOSTIC MARKET	138
SCREENING TESTS	138
PSA TESTING: YES OR NO CONTROVERSY	138
PROSTATE CANCER MARKET SIZE	140
<i>TABLE 48 TYPE OF DIAGNOSTIC TESTS</i>	140
PROSTATE CANCER SCREENING MARKET	140
PSA Test and Market	140
<i>TABLE 49 GLOBAL PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	141
<i>FIGURE 21 GLOBAL PSA TEST SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	141
<i>TABLE 50 U.S. PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	142
<i>FIGURE 22 U.S. PSA TEST SALES AND FORECAST, 2011-2017 (\$ MILLIONS)</i>	142
<i>TABLE 51 EUROPEAN PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	142
<i>FIGURE 23 EUROPEAN PSA TEST SALES AND FORECAST, 2011-2017 (\$ MILLIONS)</i>	142
<i>TABLE 52 CANADIAN PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	143
<i>FIGURE 24 CANADIAN PSA TEST SALES AND FORECAST, 2011-2017 (\$ MILLIONS)</i>	143
<i>TABLE 53 OTHER COUNTRIES: PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	144
<i>FIGURE 25 OTHER COUNTRIES: PSA TEST SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	144
DRE MARKET	145
<i>TABLE 54 GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	145
<i>FIGURE 26 GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	145
<i>TABLE 55 U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	146
<i>FIGURE 27 U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	147
<i>TABLE 56 DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE WORLD (EXCLUDING THE U.S.), THROUGH 2017 (\$ MILLIONS)</i>	147
<i>FIGURE 28 DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE WORLD (EXCLUDING THE U.S.), 2010-2017 (\$ MILLIONS)</i>	148
MARKET FOR PROSTATE BIOPSY	148
<i>TABLE 57 GLOBAL COST OF PROSTATE BIOPSIES, THROUGH 2017 (\$ MILLIONS)</i>	148
<i>FIGURE 29 GLOBAL COST OF PROSTATE BIOPSIES, 2010-2017 (\$ MILLIONS)</i>	148
<i>TABLE 58 U.S. COST OF PROSTATE BIOPSIES, THROUGH 2017 (\$ MILLIONS)</i>	149
<i>FIGURE 30 U.S. COST OF PROSTATE BIOPSIES, 2010-2017 (\$ MILLIONS)</i>	149
<i>TABLE 59 COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE U.S.), THROUGH 2017 (\$ MILLIONS)</i>	150

TOPIC	PAGE NO.
<i>FIGURE 31 COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE U.S.), 2010-2017 (\$ MILLIONS)</i>	151
<i>TABLE 60 GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	151
<i>FIGURE 32 GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, 2010-2017 (\$ MILLIONS)</i>	151
<i>TABLE 61 GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	152
<i>FIGURE 33 GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	152
PSA and DRE Manufacturers and Market	153
<i>TABLE 62 MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER DIAGNOSTICS MARKET SHARE, 2012 (\$ MILLIONS)</i>	154
NEW TESTS ON THE HORIZON	154
Myriad Genetics	154
Prostate Health Index	154
AnalizaDx	155
MDxHealth and PLUS Diagnostics	155
Opko Health	155
<i>TABLE 63 LIST OF AVAILABLE PROSTATE NOMOGRAMS</i>	156
Genomic Health	156
MDxHealth	156
Caris Life Sciences	156
Gen-Probe	157
PROSTATE CANCER DIAGNOSTIC IMAGING MARKET	157
<i>TABLE 64 GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, THROUGH 2017 (\$ MILLIONS)</i>	158
<i>FIGURE 34 GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, 2010-2017 (\$ MILLIONS)</i>	158
<i>TABLE 65 MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER IMAGING DEVICES MARKET SHARE, 2012 (\$ BILLIONS)</i>	159
CHAPTER 10 THE PROSTATE TREATMENT MARKET	161
TREATMENT PLAN FOR PROSTATE CANCER	161
PROSTATE CANCER THERAPIES: THREE LEADING PROSTATE CANCER THERAPIES	161
<i>TABLE 66 COST OF THE THREE LEADING PROSTATE CANCER THERAPIES, 2012</i>	162
PROSTATE CANCER SURGERY AND RADIOTHERAPY MARKET	162
<i>TABLE 67 SURGICAL DEVICE COMPANIES: KEY PLAYERS</i>	163
<i>TABLE 68 GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	164
<i>FIGURE 35 GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	164
RADIOTHERAPY MARKET	164
<i>TABLE 69 GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND SALES, 2010-2017 (\$ MILLIONS)</i>	165
<i>FIGURE 36 GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND SALES, 2010-2017 (\$ MILLIONS)</i>	165
PROSTATE CANCER SURGICAL DEVICE MARKET	165
BRACHYTHERAPY MARKET	166
<i>TABLE 70 GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, THROUGH 2017 (\$ MILLIONS)</i>	166

TOPIC	PAGE NO.
<i>FIGURE 37 GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, 2010-2017 (\$ MILLIONS)</i>	166
<i>PROSTATECTOMY MARKET</i>	167
<i>TABLE 71 GLOBAL INCIDENCE OF PROSTATE CANCER, THROUGH 2017 (IN THOUSANDS)</i>	167
<i>FIGURE 38 GLOBAL INCIDENCE OF PROSTATE CANCER, 2008-2017 (IN THOUSANDS)</i>	167
<i>TABLE 72 GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009-2017 (IN THOUSANDS)</i>	168
<i>FIGURE 39 GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009-2017 (IN THOUSANDS)</i>	168
<i>TABLE 73 GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	169
<i>FIGURE 40 GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	169
<i>TABLE 74 GLOBAL CASES OF ROBOTIC PROSTATECTOMIES PERFORMED PER YEAR, 2009-2017 (IN THOUSANDS)</i>	170
<i>FIGURE 41 GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-2017 (IN THOUSANDS)</i>	170
<i>TABLE 75 GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	171
<i>FIGURE 42 GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	171
<i>TABLE 76 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, THROUGH 2017 (IN THOUSANDS)</i>	172
<i>FIGURE 43 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, 2009-2017 (IN THOUSANDS)</i>	172
<i>TABLE 77 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	172
<i>FIGURE 44 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	173
<i>U.S. UROLOGICAL MARKET</i>	173
<i>TABLE 78 U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	173
<i>FIGURE 45 U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	173
<i>U.S. Market for Brachytherapy Devices</i>	174
<i>TABLE 79 U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	174
<i>FIGURE 46 U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	174
<i>TABLE 80 PROSTATE CANCER INCIDENCE IN THE U.S., 2008-2017 (IN THOUSANDS)</i>	175
<i>FIGURE 47 PROSTATE CANCER INCIDENCE IN THE U.S., 2008-2017 (IN THOUSANDS)</i>	176
<i>TABLE 81 U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	176
<i>FIGURE 48 U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	177
<i>TABLE 82 PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009-2017 (IN THOUSANDS)</i>	177
<i>FIGURE 49 PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009-2017 (IN THOUSANDS)</i>	177
<i>TABLE 83 U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	178
<i>FIGURE 50 U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	178

TOPIC	PAGE NO.
PROSTATE CANCER DEVICE MARKET IN ASIA AND LATIN AMERICA	179
MARKET: PROSTATE CANCER DRUGS	180
GLOBAL ONCOLOGY THERAPEUTICS MARKET	180
<i>TABLE 84 GLOBAL CANCER MARKET, THROUGH 2017 (\$ MILLIONS)</i>	181
<i>FIGURE 51 GLOBAL CANCER MARKET, 2010-2017 (\$ MILLIONS)</i>	181
New Approaches to Treat Prostate Cancer	181
CYTOTOXIC THERAPIES MARKET	182
<i>TABLE 85 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)</i>	182
<i>TABLE 86 CYTOTOXIC THERAPIES MARKET INDICATIONS</i>	183
<i>TABLE 87 EXPIRY OF PATENTS ON MAJOR CYTOTOXIC DRUGS</i>	183
<i>TABLE 88 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017 (\$ MILLIONS)</i>	184
<i>FIGURE 52 U.S. CYTOTHERAPEUTICS MARKET, 2010-2017 (\$ MILLIONS)</i>	184
<i>TABLE 89 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017 (\$ MILLIONS)</i>	184
<i>FIGURE 53 EUROPEAN CYTOTHERAPEUTICS MARKET, 2010-2017 (\$ MILLIONS)</i>	184
<i>TABLE 90 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017 (\$ MILLIONS)</i>	185
<i>FIGURE 54 JAPANESE CYTOTHERAPEUTICS MARKET, 2010-2017 (\$ MILLIONS)</i>	186
<i>TABLE 91 MAJOR CYTOTOXIC BRANDS SALES, 2011 (\$ MILLIONS)</i>	186
PROSTATE CANCER INCIDENCE AND IMPACT ON MARKET	186
Prostate Cancer Market Size	187
<i>TABLE 92 PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, THROUGH 2017 (\$ MILLIONS)</i>	187
<i>FIGURE 55 PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, 2010-2017 (\$ MILLIONS)</i>	188
Cost of Prostate Cancer Therapy, Care and Management	188
CURRENT PROSTATE CANCER THERAPEUTICS	189
<i>TABLE 93 PROSTATE CANCER DRUG MARKET, THROUGH 2017 (\$ MILLIONS)</i>	189
<i>FIGURE 56 PROSTATE CANCER DRUG MARKET, 2010-2017 (\$ MILLIONS)</i>	189
<i>TABLE 94 PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, THROUGH 2017 (\$ MILLIONS)</i>	190
<i>FIGURE 57 PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, 2010-2017 (\$ MILLIONS)</i>	190
GENERIC PROSTATE CANCER DRUGS	190
NEWER THERAPIES ON THE MARKET	191
<i>TABLE 95 U.S. PROSTATE CANCER MARKET: PATIENTS AND TREATMENT STRATEGIES</i>	191
RECENT DRUG APPROVALS AND MARKET	192
<i>TABLE 96 NEW DRUGS AND SALES FORECAST, 2017 (\$ MILLIONS)</i>	193
PROSTATE CANCER: THERAPEUTIC DRUGS LANDSCAPE	193
<i>TABLE 97 GLOBAL SALES AND FORECAST: KEY PROSTATE CANCER DRUGS, 2010-2012 (\$ MILLIONS)</i>	193
MARKET FOR CHEMOTHERAPY	193
<i>TABLE 98 GLOBAL PROSTATE CANCER CHEMOTHERAPY DRUGS</i>	194
<i>TABLE 99 GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	194
<i>FIGURE 58 GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	194
MARKET FOR CHEMOTHERAPY DRUGS FOR PROSTATE CANCER	195
Taxotere/Docetaxel	195
<i>TABLE 100 KEY CHEMOTHERAPEUTIC DRUGS FOR PROSTATE CANCER: SALES AND FORECAST, 2010-2012 (\$ MILLIONS)</i>	196

TOPIC	PAGE NO.
Cabazitaxel/Jevtana	196
Mitoxantrone (Novantrone)	196
Vinorelbine (Navelbine)	196
Estramustine (Emcyt)	197
MARKET FOR HORMONE THERAPY	197
<i>TABLE 101 GLOBAL PROSTATE CANCER HORMONAL THERAPY DRUGS</i>	197
<i>TABLE 102 HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	197
<i>FIGURE 59 HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	197
<i>TABLE 103 GENERICS: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	198
HORMONE THERAPY DRUGS	199
Casodex or Bicalutamide	199
<i>TABLE 104 CASODEX SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	199
<i>FIGURE 60 CASODEX SALES AND FORECAST, 2011-2017 (\$ MILLIONS)</i>	200
Zytiga/Abiraterone	200
<i>TABLE 105 ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012 (\$ MILLIONS)</i>	200
<i>FIGURE 61 ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012 (\$ MILLIONS)</i>	201
<i>TABLE 106 GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011-2017 (\$ MILLIONS)</i>	201
<i>FIGURE 62 GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011-2017 (\$ MILLIONS)</i>	201
Xtandi or Enzalutamide	202
Flutamide	202
<i>TABLE 107 GLOBAL MARKET FOR FLUTAMIDE, 2009 AND 2010 (\$ MILLIONS)</i>	203
Nilutamide	203
Triptorelin	203
<i>TABLE 108 GLOBAL MARKET FOR TRIPTORELIN, 2009 AND 2010 (\$ MILLIONS)</i>	203
Leuprolide Acetate	203
<i>TABLE 109 GLOBAL MARKET FOR LEUPROLIDE ACETATE, 2009 AND 2010 (\$ MILLIONS)</i>	204
Zoladex	204
<i>TABLE 110 GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	204
<i>FIGURE 63 GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)</i>	204
Degarelix Acetate	205
MARKET FOR IMMUNOTHERAPY	205
<i>TABLE 111 GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	205
<i>FIGURE 64 GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	205
Provenge	206
<i>TABLE 112 PROVENGE ANNUAL SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	206
<i>FIGURE 65 PROVENGE ANNUAL SALES AND FORECAST, 2010-2017 (\$ MILLIONS)</i>	206
Provenge and Future Growth	207
Provenge and Abiraterone Competition	208
PROSTATE CANCER CARE MARKET	208
<i>TABLE 113 GLOBAL MARKET FOR PROSTATE CANCER BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	209
<i>FIGURE 66 GLOBAL MARKET FOR PROSTATE CANCER BY REGION, 2012 AND 2017 (\$ MILLIONS)</i>	209

TOPIC	PAGE NO.
<i>TABLE 114 PROSTATE CANCER CARE MARKET IN EUROPE, THROUGH 2017 (\$ MILLIONS)</i>	210
<i>FIGURE 67 PROSTATE CANCER CARE MARKET IN EUROPE, 2012 AND 2017 (\$ MILLIONS)</i>	210
<i>TABLE 115 U.S. PROSTATE CANCER CARE MARKET, THROUGH 2017 (\$ MILLIONS)</i>	210
<i>FIGURE 68 U.S. PROSTATE CANCER CARE MARKET, 2012 AND 2017 (\$ MILLIONS)</i>	210
<i>TABLE 116 PROSTATE CANCER CARE MARKET IN CANADA, THROUGH 2017 (\$ MILLIONS)</i>	211
<i>FIGURE 69 PROSTATE CANCER CARE MARKET IN CANADA, 2012 AND 2017 (\$ MILLIONS)</i>	211
CONCLUSIONS	212
<i>TABLE 117 GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)</i>	212
<i>FIGURE 70 GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, 2010 - 2017 (\$ MILLIONS)</i>	213
CHAPTER 11 EMERGING PROSTATE CANCER DRUGS	215
<i>TABLE 118 EMERGING PRODUCTS FOR PROSTATE CANCER</i>	215
CABOZANTINIB	215
XGEVA	215
CUSTIRSEN	216
TASQUINIMOD	216
SPRYCEL	216
TAK-700	217
PROSTVAC	218
ALPHARADIN	218
AVODART	218
DCVAX-PROSTATE	219
CONCLUSIONS	219
CHAPTER 12 PROSTATE CANCER PATENTS	222
<i>TABLE 119 PROSTATE CANCER PATENT TRENDS, 2002-2011</i>	222
<i>TABLE 120 PATENTS BY TREATMENT CATEGORY, 2002-2011</i>	223
PROSTATE CANCER DRUG PATENTS EXPIRY	223
<i>TABLE 121 EXPIRY OF PATENTS ON MAJOR BRANDS</i>	224
<i>TABLE 122 LIST OF KEY DENDREON PATENTS AND PATENT APPLICATIONS</i>	225
NEW PATENT APPLICATIONS	225
CZ BioMed Corp.	225
Adamis Pharmaceuticals	225
Antisense Therapeutics	226
CHAPTER 13 RESEARCH AND INNOVATIONS IN TECHNOLOGY	228
NEW THERAPEUTIC DEVELOPMENTS	228
ONCOGENEX	228
MEDIVATION	228
SPECTRUM PHARMACEUTICALS	229
NEW DEVELOPMENTS IN DIAGNOSTIC TESTING FOR PSA	230
GENOMIC HEALTH	230
NEW MRI TECHNOLOGY	231
HIGH-INTENSITY FOCUSED ULTRASOUND	231
CONCLUSIONS	231

TOPIC	PAGE NO.
CHAPTER 14 SELECTED COMPANY PROFILES	234
ABBOTT LABORATORIES	234
ACTIVE BIOTECH AB	234
ALGETA	234
AMGEN	235
ASTELLAS PHARMA US	235
ASTRAZENECA	235
ATRIX LABORATORIES	236
BAVARIAN NORDIC A/S	236
BAYER HEALTHCARE PHARMACEUTICALS	236
BRISTOL-MYERS SQUIBB	236
C.R. BARD	237
CZ BIOMED CORP.	237
DENDREON CORP.	237
DIAGNOCURE	238
EXELIXIS	238
GE HEALTHCARE	239
GENOMIC HEALTH	240
GLAXOSMITHKLINE	240
HOLOGIC	240
INTUITIVE SURGICAL	241
JOHNSON & JOHNSON	241
MEDIVATION	242
MILLENNIUM PHARMACEUTICALS	242
MYRIAD GENETICS	242
NORTHWEST BIOTHERAPEUTICS	243
ONCOGENEX	243
OPKO HEALTH	244
PFIZER	244
SANOFI	244
SIEMENS AG	245
SPECTRUM PHARMACEUTICALS	245
VARIAN MEDICAL SYSTEMS	245
CHAPTER 15 REFERENCES	248

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL PROSTATE CANCER MARKET, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008	9
TABLE 2 GROWTH FACTORS IMPLICATED IN PROSTATE CANCER	15
TABLE 3 PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI	17
TABLE 4 IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER	18
TABLE 5 MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION	19
TABLE 6 WHY PSA TESTING?	28
TABLE 7 PROSTATE CANCER: MAJOR POINTS	30
TABLE 8 ACS RECOMMENDATIONS FOR THE EARLY DETECTION OF CANCER IN AVERAGE-RISK, ASYMPTOMATIC INDIVIDUALS	33
TABLE 9 PSA TEST: WHY AND WHEN?	35
TABLE 10 AGE-SPECIFIC REFERENCE RANGES FOR SERUM PSA (NG/ML)	37
TABLE 11 OTHER CAUSES OF CHANGES IN PSA LEVEL	38
TABLE 12 IMPROVEMENTS TO THE PSA TEST	40
TABLE 13 PROSTATE CANCER: DIAGNOSIS AND TREATMENT STRATEGY	50
TABLE 14 PROSTATE CANCER TESTS	51
TABLE 15 TREATMENT OPTIONS FOR PROSTATE CANCER	63
TABLE 16 FACTORS FOR PROSTATE CANCER TREATMENT PLANNING	64
TABLE 17 GUIDE TO PROSTATE CANCER DIAGNOSIS AND MANAGEMENT	64
TABLE 18 TYPES OF SURGERY	65
TABLE 19 ADVANTAGES AND DISADVANTAGES OF RADICAL PROSTATECTOMY	66
TABLE 20 ADVANTAGES AND DISADVANTAGES OF INTERSTITIAL BRACHY THERAPY	68
TABLE 21 ADVANTAGES AND DISADVANTAGES OF EXTERNAL BEAM RADIOTHERAPY	69
TABLE 22 ADVANTAGES AND DISADVANTAGES OF CRYOTHERAPY	70
TABLE 23 ADVANTAGES AND DISADVANTAGES OF ULTRASOUND	71
TABLE 24 HORMONE THERAPY	72
TABLE 25 STAGE I PROSTATE CANCER	79
TABLE 26 STAGE II PROSTATE CANCER	79
TABLE 27 STAGE III PROSTATE CANCER	80
TABLE 28 STAGE IV PROSTATE CANCER	80
TABLE 29 THERAPEUTICS FOR PROSTATE CANCER TREATMENT	82
TABLE 30 APPROVED FDA PROSTATE CANCER DRUGS	83
TABLE 31 COMMON DRUGS FOR TREATMENT OF PROSTATE CANCER	84
TABLE 32 THERAPEUTIC AGENTS FOR PROSTATE CANCER UNDER CLINICAL DEVELOPMENT	116
TABLE 33 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 (MILLIONS)	119
TABLE 34 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (IN THOUSANDS)	121
TABLE 35 GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008	124
TABLE 36 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030	126
TABLE 37 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011	127
TABLE 38 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030	128
TABLE 39 INCIDENCE RATES BY RACE IN THE U.S., 2005-2009 (PER 100,000 MEN)	128
TABLE 40 ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030	129
TABLE 41 MORTALITY RATES BY RACE IN THE U.S., 2005-2009 (PER 100,000 MEN)	130
TABLE 42 DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS FOR MALES OF ALL RACES, 2002-2008 (%)	131

TABLE HEADING	PAGE NO.
TABLE 43 RELATIVE SURVIVAL RATE FOR PROSTATE CANCER PATIENTS	131
TABLE 44 FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT THE TIME OF DIAGNOSIS (%)	132
TABLE 45 ESTIMATED PROSTATE CANCER IN CANADA, 2012	132
TABLE 46 ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008	133
TABLE 47 PROSTATE CANCER DEATHS IN THE U.K., RATE PER 100,000 PEOPLE, 2010	135
TABLE 48 TYPE OF DIAGNOSTIC TESTS	140
TABLE 49 GLOBAL PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	141
TABLE 50 U.S. PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	142
TABLE 51 EUROPEAN PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	142
TABLE 52 CANADIAN PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	143
TABLE 53 OTHER COUNTRIES: PSA TEST SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	144
TABLE 54 GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	145
TABLE 55 U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	146
TABLE 56 DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE WORLD (EXCLUDING THE U.S.), THROUGH 2017 (\$ MILLIONS)	147
TABLE 57 GLOBAL COST OF PROSTATE BIOPSIES, THROUGH 2017 (\$ MILLIONS)	148
TABLE 58 U.S. COST OF PROSTATE BIOPSIES, THROUGH 2017 (\$ MILLIONS)	149
TABLE 59 COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE U.S.), THROUGH 2017 (\$ MILLIONS)	150
TABLE 60 GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, THROUGH 2017 (\$ MILLIONS)	151
TABLE 61 GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	152
TABLE 62 MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER DIAGNOSTICS MARKET SHARE, 2012 (\$ MILLIONS)	154
TABLE 63 LIST OF AVAILABLE PROSTATE NOMOGRAMS	156
TABLE 64 GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, THROUGH 2017 (\$ MILLIONS)	158
TABLE 65 MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER IMAGING DEVICES MARKET SHARE, 2012 (\$ BILLIONS)	159
TABLE 66 COST OF THE THREE LEADING PROSTATE CANCER THERAPIES, 2012	162
TABLE 67 SURGICAL DEVICE COMPANIES: KEY PLAYERS	163
TABLE 68 GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	164
TABLE 69 GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND SALES, 2010-2017 (\$ MILLIONS)	165
TABLE 70 GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, THROUGH 2017 (\$ MILLIONS)	166
TABLE 71 GLOBAL INCIDENCE OF PROSTATE CANCER, THROUGH 2017 (IN THOUSANDS)	167
TABLE 72 GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009-2017 (IN THOUSANDS)	168
TABLE 73 GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	169
TABLE 74 GLOBAL CASES OF ROBOTIC PROSTATECTOMIES PERFORMED PER YEAR, 2009-2017 (IN THOUSANDS)	170
TABLE 75 GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	171

TABLE HEADING	PAGE NO.
TABLE 76 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, THROUGH 2017 (IN THOUSANDS)	172
TABLE 77 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	172
TABLE 78 U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	173
TABLE 79 U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	174
TABLE 80 PROSTATE CANCER INCIDENCE IN THE U.S., 2008-2017 (IN THOUSANDS)	175
TABLE 81 U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	176
TABLE 82 PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009-2017 (IN THOUSANDS)	177
TABLE 83 U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	178
TABLE 84 GLOBAL CANCER MARKET, THROUGH 2017 (\$ MILLIONS)	181
TABLE 85 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	182
TABLE 86 CYTOTOXIC THERAPIES MARKET INDICATIONS	183
TABLE 87 EXPIRY OF PATENTS ON MAJOR CYTOTOXIC DRUGS	183
TABLE 88 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017 (\$ MILLIONS)	184
TABLE 89 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017 (\$ MILLIONS)	184
TABLE 90 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017 (\$ MILLIONS)	185
TABLE 91 MAJOR CYTOTOXIC BRANDS SALES, 2011 (\$ MILLIONS)	186
TABLE 92 PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, THROUGH 2017 (\$ MILLIONS)	187
TABLE 93 PROSTATE CANCER DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	189
TABLE 94 PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, THROUGH 2017 (\$ MILLIONS)	190
TABLE 95 U.S. PROSTATE CANCER MARKET: PATIENTS AND TREATMENT STRATEGIES	191
TABLE 96 NEW DRUGS AND SALES FORECAST, 2017 (\$ MILLIONS)	193
TABLE 97 GLOBAL SALES AND FORECAST: KEY PROSTATE CANCER DRUGS, 2010-2012 (\$ MILLIONS)	193
TABLE 98 GLOBAL PROSTATE CANCER CHEMOTHERAPY DRUGS	194
TABLE 99 GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	194
TABLE 100 KEY CHEMOTHERAPEUTIC DRUGS FOR PROSTATE CANCER: SALES AND FORECAST, 2010-2012 (\$ MILLIONS)	196
TABLE 101 GLOBAL PROSTATE CANCER HORMONAL THERAPY DRUGS	197
TABLE 102 HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	197
TABLE 103 GENERICS: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	198
TABLE 104 CASODEX SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	199
TABLE 105 ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012 (\$ MILLIONS)	200
TABLE 106 GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011-2017 (\$ MILLIONS)	201
TABLE 107 GLOBAL MARKET FOR FLUTAMIDE, 2009 AND 2010 (\$ MILLIONS)	203
TABLE 108 GLOBAL MARKET FOR TRIPTORELIN, 2009 AND 2010 (\$ MILLIONS)	203
TABLE 109 GLOBAL MARKET FOR LEUPROLIDE ACETATE, 2009 AND 2010 (\$ MILLIONS)	204
TABLE 110 GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	204
TABLE 111 GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	205

TABLE HEADING	PAGE NO.
TABLE 112 PROVENGE ANNUAL SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	206
TABLE 113 GLOBAL MARKET FOR PROSTATE CANCER BY REGION, THROUGH 2017 (\$ MILLIONS)	209
TABLE 114 PROSTATE CANCER CARE MARKET IN EUROPE, THROUGH 2017 (\$ MILLIONS)	210
TABLE 115 U.S. PROSTATE CANCER CARE MARKET, THROUGH 2017 (\$ MILLIONS)	210
TABLE 116 PROSTATE CANCER CARE MARKET IN CANADA, THROUGH 2017 (\$ MILLIONS)	211
TABLE 117 GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, THROUGH 2017 (\$ MILLIONS)	212
TABLE 118 EMERGING PRODUCTS FOR PROSTATE CANCER	215
TABLE 119 PROSTATE CANCER PATENT TRENDS, 2002-2011	222
TABLE 120 PATENTS BY TREATMENT CATEGORY, 2002-2011	223
TABLE 121 EXPIRY OF PATENTS ON MAJOR BRANDS	224
TABLE 122 LIST OF KEY DENDREON PATENTS AND PATENT APPLICATIONS	225

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL PROSTATE CANCER MARKET, 2010-2017 (\$ MILLIONS)	6
FIGURE 1 STRUCTURE OF CASODEX	86
FIGURE 2 CHEMICAL STRUCTURE OF ZOLADEX	89
FIGURE 3 CHEMICAL STRUCTURE OF ELIGARD	92
FIGURE 4 CHEMICAL STRUCTURE OF NILANDRON	95
FIGURE 5 CHEMICAL STRUCTURE OF FLUTAMIDE	97
FIGURE 6 CHEMICAL STRUCTURE OF TRELSTAR	99
FIGURE 7 CHEMICAL STRUCTURE OF ESTRAMUSTINE	102
FIGURE 8 CHEMICAL STRUCTURE OF FIRMAGON	104
FIGURE 9 CHEMICAL STRUCTURE OF DOCETAXEL	106
FIGURE 10 CHEMICAL STRUCTURE OF JEVTANA	109
FIGURE 11 CHEMICAL STRUCTURE OF ZYTIGA	112
FIGURE 12 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 (MILLIONS)	119
FIGURE 13 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (IN THOUSANDS)	122
FIGURE 14 GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008	125
FIGURE 15 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030	126
FIGURE 16 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011	127
FIGURE 17 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030	128
FIGURE 18 ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030	129
FIGURE 19 ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008	134
FIGURE 20 PROSTATE CANCER DEATHS IN THE U.K.: RATE PER 100,000 PEOPLE, 2010	135
FIGURE 21 GLOBAL PSA TEST SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	141
FIGURE 22 U.S. PSA TEST SALES AND FORECAST, 2011-2017 (\$ MILLIONS)	142
FIGURE 23 EUROPEAN PSA TEST SALES AND FORECAST, 2011-2017 (\$ MILLIONS)	142
FIGURE 24 CANADIAN PSA TEST SALES AND FORECAST, 2011-2017 (\$ MILLIONS)	143
FIGURE 25 OTHER COUNTRIES: PSA TEST SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	144
FIGURE 26 GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	145
FIGURE 27 U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	147
FIGURE 28 DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE WORLD (EXCLUDING THE U.S.), 2010-2017 (\$ MILLIONS)	148
FIGURE 29 GLOBAL COST OF PROSTATE BIOPSIES, 2010-2017 (\$ MILLIONS)	148
FIGURE 30 U.S. COST OF PROSTATE BIOPSIES, 2010-2017 (\$ MILLIONS)	149
FIGURE 31 COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE U.S.), 2010-2017 (\$ MILLIONS)	151
FIGURE 32 GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, 2010-2017 (\$ MILLIONS)	151
FIGURE 33 GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	152
FIGURE 34 GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, 2010-2017 (\$ MILLIONS)	158
FIGURE 35 GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	164
FIGURE 36 GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND SALES, 2010-2017 (\$ MILLIONS)	165

FIGURE TITLE	PAGE NO.
FIGURE 37 GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, 2010-2017 (\$ MILLIONS)	166
FIGURE 38 GLOBAL INCIDENCE OF PROSTATE CANCER, 2008-2017 (IN THOUSANDS)	167
FIGURE 39 GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009-2017 (IN THOUSANDS)	168
FIGURE 40 GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	169
FIGURE 41 GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-2017 (IN THOUSANDS)	170
FIGURE 42 GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	171
FIGURE 43 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, 2009-2017 (IN THOUSANDS)	172
FIGURE 44 GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	173
FIGURE 45 U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	173
FIGURE 46 U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	174
FIGURE 47 PROSTATE CANCER INCIDENCE IN THE U.S., 2008-2017 (IN THOUSANDS)	176
FIGURE 48 U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	177
FIGURE 49 PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009-2017 (IN THOUSANDS)	177
FIGURE 50 U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	178
FIGURE 51 GLOBAL CANCER MARKET, 2010-2017 (\$ MILLIONS)	181
FIGURE 52 U.S. CYTOTHERAPEUTICS MARKET, 2010-2017 (\$ MILLIONS)	184
FIGURE 53 EUROPEAN CYTOTHERAPEUTICS MARKET, 2010-2017 (\$ MILLIONS)	184
FIGURE 54 JAPANESE CYTOTHERAPEUTICS MARKET, 2010-2017 (\$ MILLIONS)	186
FIGURE 55 PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, 2010-2017 (\$ MILLIONS)	188
FIGURE 56 PROSTATE CANCER DRUG MARKET, 2010-2017 (\$ MILLIONS)	189
FIGURE 57 PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, 2010-2017 (\$ MILLIONS)	190
FIGURE 58 GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	194
FIGURE 59 HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	197
FIGURE 60 CASODEX SALES AND FORECAST, 2011-2017 (\$ MILLIONS)	200
FIGURE 61 ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012 (\$ MILLIONS)	201
FIGURE 62 GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011-2017 (\$ MILLIONS)	201
FIGURE 63 GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009-2017 (\$ MILLIONS)	204
FIGURE 64 GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	205
FIGURE 65 PROVENGE ANNUAL SALES AND FORECAST, 2010-2017 (\$ MILLIONS)	206
FIGURE 66 GLOBAL MARKET FOR PROSTATE CANCER BY REGION, 2012 AND 2017 (\$ MILLIONS)	209
FIGURE 67 PROSTATE CANCER CARE MARKET IN EUROPE, 2012 AND 2017 (\$ MILLIONS)	210
FIGURE 68 U.S. PROSTATE CANCER CARE MARKET, 2012 AND 2017 (\$ MILLIONS)	210
FIGURE 69 PROSTATE CANCER CARE MARKET IN CANADA, 2012 AND 2017 (\$ MILLIONS)	211
FIGURE 70 GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, 2010 - 2017 (\$ MILLIONS)	213